(secondQuint)Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome.

 The trial is randomized (1:1 alirocumab to placebo), double-blinded, placebo-controlled with a cross-over design.

 The trial will last 10 months and includes a 10 week washout period between study phases.

Twenty adult subjects with dyslipidemia secondary to nephrotic syndrome and treated with atorvastatin will be recruited.

 Alirocumab or placebo will be co-administered biweekly.

 Safety, efficacy chemistries, vital signs, anthropometry and monitoring for adverse events also will done at each visit.

.

 Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome@highlight

The study purpose is to determine the hypolipidemic effect of Alirocumab co-administered with atorvastatin on levels of triglyceride-rich lipoproteins and LDL compared to monotherapy with atorvastatin in patients with dyslipidemia secondary to nephrotic syndrome.

